Popular Articles

MAP Pharmaceuticals Phase 3 Trial Of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
generic viagra online
5-to-3 Majority Supports The Idea Of A Public Or Government Health Plan To Compete With Private Insurance
One of the hotly contested issues in the debate about health care reform is whether or not there should be a new government health plan to compete with the plans offered by the insurance industry to employers and individuals. This idea is strongly supported by President Obama and most Democratic members of Congress but Republican members of Congress unanimously oppose it.
News of the day
Neurim Pharmaceuticals Reports Long Term Efficacy And Safety For Circadin(R) For Insomnia In Elderly Patients
Neurim Pharmaceuticals presented the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington. The SLEEP meeting attracts the largest audience of sleep specialists in world.
Endocrinology

Massachusetts Hospital Sues State Over Cost Of Universal Care

"A hospital that serves thousands of indigent Massachusetts residents sued the state on Wednesday, charging that its costly universal health care law is forcing the hospital to cover too much of the expense of caring for the poor," according to the New York Times. The Times reports: "The hospital, Boston Medical Center, faces a $38 million deficit for the fiscal year ending in September, its first loss in five years. The suit says the hospital will lose more than $100 million next year because the state has lowered Medicaid reimbursement rates and stopped paying Boston Medical "reasonable costs" for treating other poor patients. ... The central charge in the suit is that the state has siphoned money away from Boston Medical to help pay the considerable cost of insuring all but a small percentage of residents. Three years after the law"s passage, Massachusetts has the country"s lowest percentage of uninsured residents: 2.6 percent, compared with a national average of 15 percent." The Times notes: "Low-income residents, who have benefited most from expanded access to health care, receive state-subsidized insurance, one of the most expensive aspects of the state plan. But rapidly rising costs and the battered economy have caused more problems than the state and supporters of the 2006 law - including Boston Medical - anticipated. According to the suit, Massachusetts is now reimbursing Boston Medical only 64 cents for every dollar it spends treating the poor. About 10 percent of the hospital"s patients are uninsured - down from about 20 percent before the law"s passage in 2006. But many more are on Medicaid or Commonwealth Care, the state-subsidized insurance program for low-income residents" (Goodnough, 7/15). The Boston Globe reports: "The lawsuit could influence the national debate on healthcare by warning of the potential repercussions for hospitals that treat the poor" (Kowalczyk, 7/16). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):